Related references
Note: Only part of the references are listed.Cardiotoxic effects of angiogenesis inhibitors
Stephen J. H. Dobbin et al.
CLINICAL SCIENCE (2021)
Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers
Kazuo Kobayashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs
Mei Dong et al.
ONCOLOGY LETTERS (2021)
Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients
Daan C. H. van Dorst et al.
CIRCULATION RESEARCH (2021)
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
Tatsuya Yamashita et al.
JOURNAL OF GASTROENTEROLOGY (2020)
Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities
Daiki Taguchi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline
E. Gabriela Chiorean et al.
JCO GLOBAL ONCOLOGY (2020)
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Tanios S. Bekaii-Saab et al.
LANCET ONCOLOGY (2019)
Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting
Kensei Yamaguchi et al.
ONCOLOGIST (2019)
Optimal Blood Pressure Goals in Patients With Hypertension at High Risk for Cardiovascular Events
Wilbert S. Aronow
AMERICAN JOURNAL OF THERAPEUTICS (2016)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Jose Luis Zamorano et al.
EUROPEAN HEART JOURNAL (2016)
A randomized, double-blind, placebo-controlled, Phase III study of pazopanib in patients with soft tissue sarcoma: results from the Japanese subgroup
Akira Kawai et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2016)
Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial
Yoshito Komatsu et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis
Li Sun et al.
MEDICAL ONCOLOGY (2015)
Clinical Risk Factors for the Development of Hypertension in Patients Treated With Inhibitors of the VEGF Signaling Pathway
Ole-Petter R. Hamnvik et al.
CANCER (2015)
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations
Takayuki Yoshino et al.
INVESTIGATIONAL NEW DRUGS (2015)
Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis
Zexing Wang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Pre-Existing Antihypertensive Treatment Predicts Early Increase in Blood Pressure during Bevacizumab Therapy: The Prospective AVALUE Cohort Study
Andreas Wicki et al.
ONCOLOGY RESEARCH AND TREATMENT (2014)
Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial
Takeshi Ueda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C
T. J. Price et al.
ANNALS OF ONCOLOGY (2012)
Sex Differences in Outcome with Bevacizumab Therapy Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599
Julie R. Brahmer et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
Sorafenib in advanced clear-cell renal-cell carcinoma
Bernard Escudier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Share Paper
